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Background: The relationship between cardiorespiratoryfitness (CRF) andmortality risk has typically been assessed
using a single measurement, though some evidence suggests the change in CRF over time influences risk. This evi-
dence is predominantly based on studies using estimated CRF (CRFe). The strength of this relationship using change
in directly measured CRF over time in apparently healthy men and women is not well understood.
Purpose: To examine the association of change in CRF over time, measured using cardiopulmonary exercise testing
(CPX), with all-cause and disease-specificmortality and to compare baseline and subsequent CRFmeasurements as
predictors of all-cause mortality.
Methods: Participants included 833 apparently healthy men and women (42.9 ± 10.8 years) who underwent two
maximal CPXs, the second CPX being ≥1 year following the baseline assessment (mean 8.6 years, range 1.0 to
40.3 years). Participants were followed for up to 17.7 (SD 11.8) years for all-cause-, cardiovascular disease-
(CVD), and cancer mortality. Cox-proportional hazard models were performed to determine the association be-
tween the change in CRF, computed as visit 1 (CPX1) peak oxygen consumption (VO2peak [mL·kg−1·min−1]) –
visit 2 (CPX2)VO2peak, andmortality outcomes. AWald-Chi square test of equalitywas used to compare the strength
of CPX1 to CPX2 VO2peak in predicting mortality.
Results: During follow-up, 172 participants died. Overall, the change in CPX-CRF was inversely related to all-cause,
CVD, and cancer mortality (p b 0.05). Each 1 mL·kg−1·min−1 increase was associated with a ~11, 15, and 16% (all
p b 0.001) reduction in all-cause, CVD, and cancer mortality, respectively. The inverse relationship between CRF
and all-cause mortality was significant (p b 0.05) when men and women were examined independently, after
adjusting for years since first CPX, baseline VO2peak, and age. Further, the Wald Chi-square test of equality found
CPX2 VO2peak to be a significantly stronger predictor of all-cause mortality than CPX1 VO2peak (p b 0.05).
Conclusion: The change in CRF over timewas inversely related tomortality outcomes, andmortality was better pre-
dicted by CRF measured at subsequent test than CPX1 CRF. These findings emphasize the importance of adopting
lifestyle behaviors that promote CRF, as well as support the need for routine assessment of CRF in clinical practice
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Healthy lifestyles are gaining increased recognition in clinical and
public health settings.1,2 Cardiorespiratory fitness (CRF) is a key out-
come measure associated with healthy lifestyles. Evidence has consis-
tently shown CRF to be a strong and independent predictor of chronic
disease, including CVD, cancer, and all-cause mortality.3–7 Several stud-
ies have shown CRF to be a better predictor of health outcomes in both
healthy and clinical populations than traditional cardiovascular disease
(CVD) risk factors that are commonly assessed clinically.4,5
CRF is a modifiable risk factor that is influenced by lifestyle and
health parameters, including exercise training status.8–11 Improve-
ments in CRF have been shown to result in beneficial changes in tradi-
tional risk factors and health.12–14 Additionally, there is growing
evidence suggesting changes in estimated CRF (CRFe) over time
(N1 year), are associated with changes in mortality risk.15–21 Since CRF
may change over time, the routine assessment of CRFmayhave stronger
prognostic value and use as a mortality risk assessment tool than a sin-
gle CRF measurement.
Past studies assessing the association between the change in CRF
over time and mortality have predominately used CRFe from exercise
test workload or duration.4,15–17,19–21 Additionally, past studies have
only assessed men and used cohort specific reference values to define
CRF thresholds.4,15–17,19,21 These factors may limit the generalizability
of the findings and clear understanding of this relationship.22,23 Further,
the estimation errors associated with CRFe may impact an individual's
risk assessment, reducing its sensitivity.
Recent scientific statements and reviews have emphasized the need
for more studies assessing the association between directly measured
CRF, obtained from cardiopulmonary exercise testing (CPX-CRF) which
is considered the gold standard method, and mortality outcomes.24,25
Only two studies have used CPX-CRF as a baseline measure and only
one study has examined the association between the change in CPX-
CRF and mortality apparently healthy individuals.3,15 Laukkanen et al.
studied 579 men (age range: 42–60 y) from eastern Finland who per-
formed two CPX with cycle ergometry 11-years apart.15 After a median
follow-up of 13.3 years from the second CPX, a graded relationship was
found, where each 1 MET higher change was associated with a 30%
lower risk of all-cause mortality. The findings from this study of middle-
aged Finnish men tested using a cycle ergometer protocol may not be
generalizable to other populations, including women, nor to CPX-CRF
measured using treadmill as the mode for testing. Therefore, the primary
aimof this studywas to examine the association of the change in CPX-CRF
over time (N1 year between CRF measures) with all-cause and disease-
specificmortality in a cohort of apparently healthymen andwomen. Sec-
ondly, this study sought to determine if a secondmeasure of CRF, N 1 year
after the first, improves the prediction of mortality risk across time above
a single measure.
Methods
The study cohort included 833 apparently healthy participants (552
men, 281 women; baseline mean age: 42.9 ± 10.8, range 18.0–
82.0 years) obtained from the Ball State Adult fitness Longitudinal Life-
style STudy (BALL ST) cohort. Participants were self-referred either to
the Ball State University-Adult Physical Fitness Program, a community-
based exercise program or were research subjects in clinical exercise
physiology related studies who gave written informed consent for their
data to be used for research. Participants were considered apparently
healthy, as all were free from known CVD (history of cardiac arrest, coro-
nary artery disease, heart failure, myocardial infarction, and stroke) and
cancer at baseline or follow-up. CVD diagnosis was self-reported and ver-
ified by written physician confirmation. All participants completed two
health and fitness assessments between 1969 and 2017, each including
a CPX achieving a peak effort criteria of a respiratory exchange ratio
≥ 1.0 during both CPX1 and CPX2. These two exams were ≥ 1 year apart
(mean 8.6 years, range 1.0 to 40.3 years). This study was reviewed by
the Ball State University Institutional Review Board and determined ex-
empt as only de-identified data were used.
Resting health assessment
A full description of the procedures involved in the resting health
and fitness measurements performed prior to both CPXs have been ex-
plained previously.26,27 In summary, participants completed a health
history questionnaire, providing demographic information, personal
and family medical history, medication usage, and lifestyle behaviors.
Information gained from the questionnaire was used to screen for med-
ical contraindications and/or physical limitations to CPX.
Lifestyle behaviors of physical activity (PA) and smoking were self-
reported. PA status was classified as inactive or active, with active
being designated if participants reported engagement in regular PA,
meeting the US aerobic PA guidelines for adults.28 Smoking status was
categorized as current smoker, including those that used cigarettes or
quit within the past year, or a non-smoker at CPX1.
Clinical measurements including, resting heart rate, blood pressure,
anthropometrics (height, weight, waist circumference), 12‑lead electro-
cardiogram, and blood chemistry (≥ 8 h post-prandial), were performed
by trained technicians using standardized laboratory procedures. These
measurements were used to determine the presence of risk factors, in-
cluding obesity, hypertension, dyslipidemia, and impaired fasting glu-
cose, defined according to current accepted atherosclerotic CVD risk
factor criteria.29
Assessment of CRF
A more thorough description of the procedures used to assess CRF
have been described previously.3,26 In summary, at visit one CPX was
performed using a standardized treadmill or cycle protocol, to deter-
mine peak oxygen consumption (VO2peak). The mode of exercise was
chosen based on participant preference, comfort, and the presence of
functional limitations as determined through the health history ques-
tionnaire. Standardized procedures were followed for metabolic cart
calibration and all CPXs were supervised by trained clinical exercise
physiologists, with additional medical supervision when appropriate.30
Participants were encouraged to exercise to volitional fatigue and a re-
spiratory exchange ratio ≥ 1.0was used as anobjective indicator ofmax-
imal effort.
All participants were re-tested in the Clinical Exercise Physiology
laboratory ≥1 year after their baseline assessment. At this second assess-
ment, both CPX-CRF and resting health and fitness measurements were
reassessed following the same standardized procedures and criteria as
at baseline. CPX2 was also performed using the same mode of exercise
as at CPX1.
Outcomes and follow-up
All participants were followed from the date of their CPX2 through
2017 or until date of death for all-cause mortality or December 31,
2016 for disease-specific mortality. The National Death Index (NDI)
was the primary data source for obtaining vital status between 1979
and 2016, providing date of death and cause of death. There were no
deaths reported in the cohort prior to 1979. Deaths occurring after
2016 (n = 10) were confirmed by obituary review. The underlying
cause of death determined from the NDI report was coded according
to the International Classification of Diseases (ICD), 9th revision, prior
to 1999 and the ICD, 10th revision, from 1999 to 2016.31,32 CVDmortal-
ity was defined by the ICD, 9th revision codes 390.0 to 449.9 and ICD,
10th revision codes I00.0 to I78.9. Cancer mortality was defined by the
ICD, 9th revision codes 140.0 to 239.0 and ICD, 10th revision codes
C00.0 to D49.9. For all other ICD codes, cause of death was classified as
other.
Statistical analysis
SPSS V. 24 (SPSS, Inc., Chicago, IL) and SAS V. 9.3, were used for all
statistical analyses. Descriptive statistics were performed to summarize
characteristics of the cohort and a univariate analysis of variance
(ANOVA) and chi-square goodness of fit test were used when appropri-
ate to test for significant differences between sexes and vital status (liv-
ing vs. deceased). Paired t-tests were used to assess the differences
between resting health and fitness and CPX measurements. To deter-
mine significant differences between CPX1 and CPX2 measures, all de-
scriptive data were normalized to account for differences in the
number of years between subject's CPXs. Cox proportional hazard
models were used to determine hazard ratios (HR) and 95% confidence
intervals (CI) associated with the change in CRF as related to all-cause,
CVD, and cancer mortality. Sex-specific hazardmodels were used to de-
termine the HR related to all-cause mortality according to change in
CRF. There were an inadequate number of cases of CVD and cancer spe-
cificmortality for sex-specific analyses. CRFwas expressed as VO2peak in
mL·kg−1·min−1 and the continuous change in CRF was computed as
the difference in VO2peak between CPX1 and CPX2. The Cox proportional
hazard models were fit to the data and run adjusted for years between
CPXs (model 1), additionally controlled for CPX1 VO2peak, age, and sex
(model 2), and then with further adjustment for the change in tradi-
tional CVD risk factors (model 3; dyslipidemia, hypertension, impaired
fasting glucose, obesity, physical inactivity and smoking status), which
were categorized by the change in each risk factor status between
CPX1 and CPX2. The Cox models were obtained separately on a sub-
group of the cohortwith ≥5 years (n=491) between CPXs to determine
if the relationship remained consistent. A Wald Chi-square test was
used to compare the coefficients estimating the relationship of CPX1
CRF to CPX2 CRF with time until death for all-cause mortality. These
models were obtained both unadjusted, and then adjusted for years be-
tween CPXs, age, and sex.
Results
Table 1 provides descriptive characteristics of the study cohort at
CPX1. Men had a higher absolute CRF than women, however, there
were no differences in their values based on age and sex specific refer-
ence standards. Additionally, men had a less favorable risk factor profile
with a higher prevalence of dyslipidemia, impaired fasting glucose, hy-
pertension, physical inactivity, and smoking (p b 0.05).
During the follow-up period (17.7 ± 11.8 years, range: 1.0–
45.8 years) 172 participants died (132 men, 40 women), with an overall
incidence rate of 11.6 deaths per 1000 person years. Themean age differ-
ence for the entire cohort between CPX1 and CPX2was 8.5 years and the
mean change in CRF was−1.8 mL·kg-1·min−1. Table 2 provides a com-
parison of the descriptive characteristics at CPX1 for participants identi-
fied as living and deceased at time of follow-up. Overall, at CPX1
participants that died during the follow-up period were older, more
likely to be obese, physically inactive, and have dyslipidemia (p b 0.05).
Additionally, at CPX1 women that died during the follow-up period
had a significantly higher prevalence of hypertension, but were less
likely to have diabetes, and men were more likely to be smokers than
their living counterparts (p b 0.05).
Results from the Cox proportional hazard models assessing risk for
all-cause, CVD, and cancer mortality according to per unit change in
VO2peak (mL·kg−1·min−1) between CPX1 and CPX2 are shown in
Table 3a. Overall, there was an inverse relationship between the change
in CRF and risk for all-cause, CVD, and cancer mortality after adjusting
for years between CPXs (model 1). After further adjustment for baseline
VO2peak, age, and sex (model 2), the strength of the association was in-
creased. The inverse association found between the change in CRF and
all-cause (p b 0.01) and disease-specific mortality (p b 0.05) outcomes
remained significant in the multivariable adjusted model (model 3).
Specifically, a 1 mL·kg−1·min−1 increase was found to be associated
with ~11%, 15%, and 16% lower risk of all-cause, CVD, and cancermortal-
ity, respectively (p b 0.001). The inverse relationship between the
change in CRF expressed as absolute VO2peak (L·min−1) and risk for
all-cause, CVD, and cancer mortality was significant (p b 0.05) for each
model.
The inverse association between change in VO2peak and all-cause
mortalitywas also present for bothmen andwomen,when assessed in-
dependently, in bothmodels 1 and 2 (Table 3b). Specifically in model 2,
a 1 mL·kg−1·min−1 increase was found to be associated with approxi-
mately a 10% and 11% lower risk of all-cause mortality in men and
women, respectively (p b 0.05). In model 3, following multivariable
Table 1
Descriptive characteristics of the BALL ST Cohort at CPX1.
Men (n = 552) Women (n = 281)
Age (years) 44.6 ± 9.8 45.0 ± 10.8
VO2peak (mL·kg−1·min−1) 36.6 ± 9.3⁎ 27.8 ± 7.3
VO2peak (L·min−1) 3.10 ± 0.03⁎ 1.90 ± 0.04
METs 10.8 ± 2.7⁎ 8.3 ± 2.2
FRIEND percentile7,8 46 ± 26 54 ± 25
Weight (kg) 87.2 ± 16.8⁎ 69.5 ± 14.6
BMI (kg·m−2) 27.2 ± 4.7 26.0 ± 5.7
Waist (cm) 84.5 ± 32.1 80.1 ± 12.8
Blood glucose (mg·dL−1) 98.1 ± 28.5⁎ 94.0 ± 19.3
Total cholesterol (mg·dL−1) 212.1 ± 46.2 202.2 ± 39.2
SBP/DBP (mm Hg) 126⁎/81⁎ ± 13/9 119/76 ± 16/11
RHR (bpm) 68 ± 13 72 ± 11
HRmax (bpm) 176 ± 16 177 ± 14
Risk factors
Obesity (%) 22 24
Impaired fasting glucose (%) 31 26
Dyslipidemia (%) 61⁎ 36
Hypertension (%) 32⁎ 21
Physical inactivity (%) 62⁎ 77
Smoking (%) 12⁎ 6
Abbreviations: BALL ST, Ball State Adult fitness program Longitudinal Lifestyle STudy (BALL
ST) cohort; BMI, body mass index; DBP, diastolic blood pressure; FRIEND, Fitness Registry
and the Importance of Exercise National Database; HRmax,maximal heart rate;METs,met-
abolic equivalents; RHR, resting heart rate; SBP, systolic blood pressure; VO2peak, peak oxy-
gen consumption. Prevalence of obesity, impaired fasting glucose, dyslipidemia,
hypertension, and physical inactivity was defined per current accepted atherosclerotic
CVD risk factor criteria.29
Data are expressed as mean ± SD or %.
⁎ p ≤ 0.05.
adjustment the strength of the association remained formenwith a 11%
lower all-cause mortality risk per 1 mL·kg−1·min−1 in VO2peak.
However, in women, the relationship was attenuated and no longer sig-
nificant in model 3 (p = 0.29).
To assess if the relationship remained consistent when assessing the
change in CRF over a longer period of time between CPXs, Cox models
were obtained on a sub-group with ≥5 years between CPX1 and CPX2.
The inverse association between the change in CRF and all-cause, CVD,
and cancer mortality was also significant in this sub-cohort (n = 491,
104 deceased) in both model 1 (HR = 0.956, 95% CI = 0.929–0.983;
HR = 0.938, 95% CI = 0.890–0.988; HR = 0.954, 95% CI = 0.906–
0.998, respectively) and in model 2 (HR = 0.931, 95% CI = 0.897–
0.967; HR = 0.923, 95% CI = 0.861–0.990; HR = 0.925, 95% CI =
0.864–0.990, respectively). Model 3 showed each 1 mL·kg−1·min−1 in-
crease in CRF to be significantly associatedwith 6% lower risk of all-cause
mortality (p b 0.01), and to be marginally associated with an 8.7% and
7.2% lower risk for CVD (p = 0.09) and cancer mortality (p = 0.10),
respectively.
Results from the Cox proportional hazard model and Wald-chi
square test of equality comparing CPX1 CRF to CPX2 CRF as predictors
for all-cause mortality are shown in Table 4. CRF measured at CPX2
was found to be a stronger predictor of all-cause mortality than the
CPX1 CRF measurement in the unadjusted model, as well as after
adjusting for years between CPXs, VO2peak measured at CPX1, age, and
sex.
Discussion
The change in CPX-derived CRF over time in apparently healthy
adults was found to be a strong predictor of all-cause, CVD, and cancer
mortality. Significant changes in mortality outcomes were seen even
with small changes in CRF (1 mL·kg−1·min−1) and were independent
of changes in traditional CVD risk factors. These results highlight the im-
portance of improving low CRF or maintaining an adequate CRF level
throughout the lifespan for both men and women.
The inverse relationship found in the current study using CPX-CRF
revealed a stronger association withmortality compared to past studies
that used CRFe. Overall, the current study found a 37.8% lower risk in all-
causemortality risk with eachMET higher change (10.8% lower risk per
1 mL·kg−1·min−1; 1 MET= 3.5 mL·kg−1·min−1), and risk reductions
of 35.4% and 27.3% per 1 MET increase in men and women when
assessed independently. To place this change in perspective, each de-
cade of age is associated with N1 MET reduction in CRF. Blair et al. stud-
ied 9777men from theAerobic Center Longitudinal Study (ACLS) cohort
who performed two preventative maximal exercise tests that were ap-
proximately 5 years apart, using CRFe.18 Results showed a 16% reduction
in all-causemortality risk per 1MET improvement. More recently, Shah
et al. assessed this relationship in 4872 young adults (54% women,
mean age 24.8 y) that performed two exercise tests, approximately
7 years after baseline.20 After approximately 20 years of follow-up, re-
sults showed that for every one minute reduction in exercise time on
themodified Balke protocol (eachminute on the exercise test is approx-
imately equal to 1 MET) there was a 21% increase in all-cause mortality.
Although differences in the strength of the association between the cur-
rent study findings and those from these past studies may result from
differences in cohort characteristics, the method used to measure CRF
may have also impacted the findings.9
Table 2
Descriptive characteristics at CPX1 of the living and deceased participants within the BALL ST cohort.
Men Women
Living (n = 420) Deceased (n = 132) Living (n = 241) Deceased (n = 40)
Age (years) 42.8 ± 9.8⁎ 49.3 ± 8.7 43.1 ± 10.4⁎ 51.8 ± 12.0
RHR (bpm) 69 ± 13 64 ± 16 72 ± 11 71 ± 11
HRmax (bpm) 178 ± 16 173 ± 16 179 ± 13⁎ 169 ± 19
VO2peak (mL·kg−1·min−1) 37.2 ± 9.6⁎ 34.1 ± 8.3 28.4 ± 7.6 27.2 ± 6.9
VO2peak (L·min−1) 3.19 ± 0.66⁎ 2.80 ± 0.65 1.92 ± 0.42 1.83 ± 0.46
METs 10.7 ± 2.7⁎ 9.7 ± 2.2 8.1 ± 2.2 7.8 ± 2.0
FRIEND percentile7,8 47 ± 27 44 ± 24 54 ± 25 57 ± 25
Weight (kg) 87.6 ± 17.2⁎ 83.7 ± 14.0 69.2 ± 14.4 68.0 ± 15.1
BMI (kg·m−2) 27.4 ± 4.8 26.3 ± 3.9 25.7 ± 5.6 25.9 ± 5.8
Waist (cm) 94.8 ± 12.6 93.3 ± 9.0 79.9 ± 12.6 79. 5 ± 14.3
Blood glucose (mg·dL−1) 97.8 ± 28.0 95.3 ± 25.7 93.7 ± 21.0 94.8 ± 11.5
Total cholesterol (mg·dL−1) 207.3 ± 45.2⁎ 228.5 ± 45.7 199.7 ± 38.9⁎ 217.3 ± 37.8
SBP/DBP (mm Hg) 125⁎/81 ± 13/9 129/83 ± 12/9 118⁎/76⁎± 14/10 127/80 ± 19/12
Risk factors
Obesity (%) 25⁎ 12 24⁎ 20
Diabetes (%) 31 35 27⁎ 22
Dyslipidemia (%) 59⁎ 68 34⁎ 45
Hypertension (%) 32 32 20⁎ 30
Physical inactivity (%) 59⁎ 68 75⁎ 85
Smoking (%) 11⁎ 16 5 6
Abbreviations: BALL ST, Ball State Adult Fitness Program Longitudinal Lifestyle STudy (BALL ST) cohort; BMI, bodymass index; CPX, cardiopulmonary exercise testing; DBP, diastolic blood
pressure; FRIEND, Fitness Registry and the Importance of Exercise National Database; HRmax,maximal heart rate;METs,metabolic equivalents; RHR, resting heart rate; SBP, systolic blood
pressure; VO2peak, peak oxygen consumption. Prevalence of obesity, impaired fasting glucose, dyslipidemia, hypertension, and physical inactivitywas defined per current accepted athero-
sclerotic CVD risk factor criteria.29
Data are expressed as mean ± SD or %.
⁎ p ≤ 0.05, living vs. deceased.
Table 3a
Hazard ratios for all-cause, CVD, and cancer mortality outcomes for BALL-ST cohort ac-
cording to change in CRF, expressed as both VO2peak and METs.
Mortality Hazard Ratio (95% CI) % reduction/mL·kg−1·min−1 % reduction/MET
All-cause mortality
Model 1 0.923⁎ (0.953–0.972) 7.7 27.0
Model 2 0.889⁎ (0.873–0.926) 11.1 38.9
Model 3 0.892⁎ (0.843–0.943) 10.8 37.8
CVD mortality
Model 1 0.900⁎ (0.863–0.939) 10.0 35.0
Model 2 0.886⁎ (0.840–0.935) 11.4 39.9
Model 3 0.853✝ (0.750–0.971) 14.7 51.5
Cancer mortality
Model 1 0.924✝ (0.887–0.962) 7.6 26.6
Model 2 0.894⁎ (0.849–0.942) 10.6 27.1
Model 3 0.861⁎ (0.774–0.957) 15.9 55.7
⁎ p ≤ 0.01.
✝ p ≤ 0.05.
A common limitation of CRFe, is the reported estimation error of ap-
proximately±1 to 2METs.9,29,33,34 Given that exercise training can result
in CRF improvements of this amount,35 this error may lead to erroneous
interpretation of one's change in CRF level (i.e. fit to fit vs. unfit to fit),
limiting the strength of the association. These limitations may be over-
come by CPX, which provides a direct, quantitative, and more accurate
measure of CRF.22,23,36 However, only one other study to date has
assessed the relationship between the change in CPX-CRF over time
(N1 year) and mortality risk in apparently healthy individuals.15 This
study assessed middle aged men (42–60 years) from eastern Finland
that performed two CPXs using cycle ergometry with 11 years between
tests. Results showed each 1 ml·kg−1·min−1 increase in CPX-CRF was
associated with a 10% lower risk of all-cause mortality after adjusting
for baseline VO2peak. The current results showed similar findings, of an
11.1% and 9.7% lower risk for all-cause mortality per 1 mL·kg−1·min−1
increase in VO2peak in the overall cohort and in men only, after similar
model adjustment, respectively. However, CRF is known to be influenced
by sex and age.22,36–38We also observed an 11.3% lower risk for all-cause
mortality per 1 mL·kg−1·min−1 increase in VO2peak in the women. The
wider age distribution, use of treadmill as a mode with CPX, and the in-
clusion of women in the current cohort, helps to advance our under-
standing of the influence CPX-CRF has on mortality outcomes across
the lifespan.
There was also a significant inverse relationship found between the
change in CRF and disease-specific mortality in the current cohort. Each
1 mL·kg−1·min−1 increase was associated with ~15% and 16% lower
risk of CVD and cancer mortality, respectively, both corresponding to
N50% lower risk per 1 MET increase. Lee et al. assessed the change in
CRFe, as related to CVD mortality in a cohort of ~14,000 men from the
ACLS cohort that performed two exercise tests.17 Results showed each
1 MET improvement was associated with a 19% reduction in CVD mor-
tality. Zhang et al. also assessed men of the ACLS cohort, examining the
relationship between the change in CRFe and cancermortality.16 Results
showed a 5% lower risk of cancer mortality with each 1 MET increase.
Discrepancies in the findings between studiesmay be due to differences
in cohort characteristics, the time period between tests, as well as
methodological factors such as the differentmethods used in determin-
ing CRF.
A recent 2016 AHA scientific statement advocated that CRF should
be considered a clinical vital sign.9 The findings from the current study
demonstrate the value of periodic measurement of CPX-CRF as the
change in CPX-CRF over time was found to improve mortality risk as-
sessment compared to one-time measure. In a cross-sectional analysis
using the current cohort assessing the relationship between baseline
CPX-CRF and all-cause mortality, there was an 11.6% lower risk per
MET increment difference, which was similar to the 13% lower risk of
all-cause mortality per MET increment difference reported in a review
by Kodama et al. of 33 studies assessing the cross-sectional relationship
between CRF and mortality.3,7 However, the magnitude of the associa-
tion between the change in CRF and all-cause mortality was found to
be greater than that found using a single measure, with a nearly 27%
lower risk per MET increase between CPX1 and CPX2. The smaller mag-
nitude of the association found in these cross-sectional analyses may be
a result of the lack of information on changes in CRF over time, espe-
cially since an expected response to identification of low CRF would
be to begin or increase exercise training. To further highlight the impor-
tance of routine CRF assessment, CRFmeasures taken at CPX1 and CPX2
were compared as predictors of mortality. The CPX2 CRF was found to
be a stronger predictor of all-cause mortality compared with the CPX1
CRF measure.
On average, CRF declines at least 1 MET per decade of age22,39 and
the current study suggests that attenuating this decline is associated
with reduced risk of mortality. Regular PA can help mitigate this age-
related reduction to preserve an adequate/acceptable CRF level for
one's age and sex. PA behavior accounts for approximately 50% of the
variation in CRF and it has been reported that individuals beginning a
moderate to vigorous aerobic exercise program can increase their CRF
by approximately 1 to 2 METs.8,35,40 On the contrary, those that reduce
their PA over time can experience lifestyle related declines in CRF,
greater than normally experienced due to increasing age.41 These
changes in PA behavior, influencing changes in CRF may potentially
alter mortality risk over time. These results can be seen as encouraging
for individuals that have low CRF, as they suggest CRF improvements,
achievable through regular PA/exercise, can reduce mortality risk.
Strengths and limitations
The study used CPX, the gold standard method for measuring CRF,
providing an accurate representation of the change in CRF over time.
Additionally, the BALL ST cohort consisted of men and women across a
wide distribution of age and risk factors. Therefore, the results may be
more representative of the population that clinicians see on a regular
basis, enhancing utilization in clinical practice. Sex-specific analyses
were also performed when assessing all-cause mortality, compared to
most studies including both men and women, which have solely
Table 3b
Hazard ratios for all-cause mortality outcomes for men and women according to change in CRF, expressed as both VO2peak and METs.
All-cause mortality Hazard ratio (95% CI) % reduction/ml·kg−1·min−1 % reduction/MET
Men
Model 1 0.934⁎✝ (0.911–0.957) 6.6 23.1
Model 2 0.903⁎ (0.874–0.933) 9.7 34.0
Model 3 0.899⁎ (0.842–0.960) 10.1 35.4
Women
Model 1 0.897⁎ (0.929–0.999) 10.3 36.1
Model 2 0.887⁎ (0.825–0.953) 11.3 39.6
Model 3 0.922 (0.793–1.072) 7.8 27.3
Abbreviations: CRF = cardiorespiratory fitness; CVD = cardiovascular disease; VO2peak = peak oxygen consumption.
Model 1 adjusted for years sincefirst CPX;Model 2 adjusted for years sincefirst CPX, CPX1VO2peak, and age in the sex-specific analyseswith the addition of sex in the overall sample;Model
3 adjusted for years since first CPX, CPX1 VO2peak, age, examination year, and change in risk factors (dyslipidemia, hypertension, impaired fasting glucose, obesity, physical inactivity, and
smoking) for the sex-specific analyses with the addition of sex when models were obtained for the overall sample.
⁎ p ≤ 0.01.
✝ p ≤ 0.05.
Table 4
Absolute parameter estimates comparing the relationship between CPX1 VO2peak and






Model 1 0.014 0.052a 0.001
Model 2 0.006 0.029a 0.001
Abbreviations: CPX, cardiopulmonary exercise testing; VO2peak, peak oxygen consumption.
Model 1 run unadjusted;Model 2 adjusted for years since first CPX, CPX1VO2peak, age, and
sex.
a Comparison of the coefficients for CPX1 VO2peak to VO2peak measured at CPX2.
adjusted for sex in statistical models. This cohort allows for a better un-
derstanding of how changes in CPX-CRFmay influence prognosis differ-
ently in men and women. Finally, the study had an extensive mortality
follow-up of 17.7 years,which adds to the knowledge base of the impact
changes in CRF across time have on mortality risk.
The limitations of the present study include a N90% non-Hispanic
white cohort. Future work is needed to confirm these findings in popu-
lations fromdiverse racial and ethnic backgrounds that are known to in-
fluence health outcomes.42 Additionally, statistical power was reduced
for sex-specific analyses when assessing disease-specific mortality,
therefore men and women were only analyzed independently when
assessing all-cause mortality outcomes. Future studies should assess
the association between the change in CRF and CVD and cancer-
specific mortality in a large cohort of men and women with greater
disease-specific mortality end-points.
Conclusion
Change inCPX-CRF over timewas inversely related to all-cause, CVD,
and cancer mortality in a cohort of apparently healthy adults. This rela-
tionship was strengthened when accounting for the change in tradi-
tional CVD risk factors, further demonstrating the importance of CRF
for determining health outcomes. These findings support the clinical
value of CPX-CRF and highlight the importance of its routine measure-
ment in clinical practice. Although clinicians should encourage all to
participate in regular PA/exercise, as a way to help improve or maintain
adequate CRF levels, these findings may be particularly promising to
those identified as low fit, as they suggest even small improvements
in CRF can have a profoundly positive impact on reducingmortality risk.
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